Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Calidi Biotherapeutics Inc shares valued at $150,000 were purchased by Schoeneck James A on Aug 21 ’25. At $2.00 per share, Schoeneck James A acquired 75,000 shares. The insider’s holdings grew to 76,134 shares worth approximately $0.13 million following the completion of this transaction.
Also, Poma Eric E purchased 25,000 shares, netting a total of over 50,000 in proceeds. Following the buying of shares at $2.00 each, the insider now holds 25,000 shares.
Before that, Leftwich Scott had added 125,000 shares to its account. In a trade valued at $250,000, the Director bought Calidi Biotherapeutics Inc shares for $2.00 each. Upon closing the transaction, the insider’s holdings increased to 125,000 shares, worth approximately $0.22 million.
As published in their initiating research note from H.C. Wainwright on November 22, 2023, Calidi Biotherapeutics Inc [CLDI] has been a Buy and the price target has been revised to $11. Analysts at Robert W. Baird started covering the stock with ‘”an Outperform”‘ outlook in a report released in early October.
Analyzing CLDI Stock Performance
On last trading session, Calidi Biotherapeutics Inc [AMEX: CLDI] rose 10.67% to $1.66. The stock’s lowest price that day was $1.47, but it reached a high of $1.69 in the same session. During the last five days, there has been a surge of approximately 5.06%. Over the course of the year, Calidi Biotherapeutics Inc shares have dropped approximately -89.52%. Shares of the company reached a 52-week high of $19.2000 on 07/09/25 and a 52-week low of $1.4100 on 09/25/25.
Support And Resistance Levels for Calidi Biotherapeutics Inc (CLDI)
According to the 24-hour chart, there is a support level at 1.5233, which, if violated, would cause prices to drop to 1.3867. In the upper region, resistance lies at 1.7433. The next price resistance is at 1.8267. RSI (Relative Strength Index) is 52.23 on the 14-day chart, showing neutral technical sentiment.
Is Calidi Biotherapeutics Inc subject to short interest?
Stocks of Calidi Biotherapeutics Inc saw a sharp steep in short interest on 2025-10-15 dropping by -0.18 million shares to 0.12 million. Data from Yahoo Finance shows that the short interest on 2025-09-15 was 0.3 million shares. A decline of -145.57% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 0.75 of the overall float, the days-to-cover ratio (short ratio) decline to 0.75.
Which companies own the most shares of Calidi Biotherapeutics Inc (CLDI)?
In terms of Calidi Biotherapeutics Inc share price expectations, FactSet research, analysts set an average price target of 5.5 in the next 12 months, up nearly 266.67% from the previous closing price of $1.5. Analysts anticipate Calidi Biotherapeutics Inc stock to reach 9 by 2025, with the lowest price target being 2.
